SB
MRNA icon

Strategic Blueprint’s Moderna MRNA Stock Holding History

Strategic Blueprint’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,175
Closed -$258K – 674
2024
Q2 		$258K Sell
2,175
-37
-2% -$4.68K 0.02% 525
2024
Q1 		$236K Sell
2,212
-8
-0.4% -$806 0.02% 541
2023
Q4 		$221K Sell
2,220
-166
-7% -$14K 0.02% 521
2023
Q3 		$246K Buy
2,386
+562
+31% +$62.7K 0.02% 467
2023
Q2 		$222K Buy
+1,824
New +$243K 0.02% 497
2023
Q1 		– Sell
-1,163
Closed -$209K – 542
2022
Q4 		$209K Buy
+1,163
New +$190K 0.02% 476
2022
Q2 		– Sell
-1,188
Closed -$205K – 537
2022
Q1 		$205K Buy
+1,188
New +$200K 0.02% 477
2021
Q3 		– Sell
-32
Closed -$8K – 966
2021
Q2 		$8K Buy
+32
New +$5.72K ﹤0.01% 1011

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Strategic Blueprint's MRNA Position: Q3 2024 in Review

Strategic Blueprint sold out of Moderna (MRNA) in Q3 2024, closing a stake of 2,175 shares — an estimated $258K sold.

Strategic Blueprint first reported a position in MRNA in Q2 2021 and held it in 8 quarters. The position peaked at $258K in Q2 2024. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Strategic Blueprint reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Strategic Blueprint sold 2,175 Moderna shares in Q3 2024, an estimated $258K.
  • Strategic Blueprint first reported a position in Moderna in Q2 2021 and held it in 8 quarters.
  • Strategic Blueprint's Moderna position peaked at $258K in Q2 2024.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Strategic Blueprint's 13F filing for Q3 2024, filed 25 Oct 2024.